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Introduction
Epigenome-wide association studies represent an opportunity to 
investigate disease-associated epigenetic variation in common 
human diseases.1 DNA methylation is the most studied form 
of epigenetic modification and it results from the addition of a 
methyl group to cytosine (5-mC) in the context of CpG dinu-
cleotides. CpG methylation has been not only observed during 
development or differentiation and in association with diseases, 
but it has also been proposed as a prerequisite to unravel dis-
ease pathogenesis and understanding complex phenotypes.2,3 In 
the past few years, a number of technologies to measure 5-mC 
profiles on a genome-wide scale became rapidly available, con-
veniently subdivided into two groups. The first group identifies 
enriched DNA methylation by making use of methylation-sensi-
tive restriction enzymes4,5 or immunoprecipitation with an anti-
body against 5-mC (MeDIP techniques6,7). The second group 
relies on bisulfite-based treatment to convert unmethylated cyto-
sines to uraciles, (i.e., MethylC-Seq,8 RRBS-seq9). In both cases, 
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microarrays and sequencing approaches have been adopted.10,11 
Sequencing-based methods allow comprehensive DNA methyla-
tion evaluation and assignment of specific states to specific alleles 
and can interrogate DNA methylation in repetitive sequences.
Array based profiling approaches represent a common option 
for genome-wide DNA methylation studies, allowing an analysis 
of a larger number of samples at an affordable cost. The sample 
size is especially relevant when considering that, in many cases, 
changes in DNA methylation are mild and the biological vari-
ability may be high. Illumina Infinium HumanMethylation450 
BeadChip (450K) is based on the Infinium Technology and con-
tains more than 480,000 probes, targeting 99% of genes and 96% 
of CpG island regions.12,13 Initial studies showed a strong correla-
tion with the previous Illumina Infinium HumanMethylation27 
BeadChip12 and high concordance between biological replicates of 
a cell line.14 Furthermore, it has been demonstrated that Illumina 
450K can detect differences of 20% in methylation with 99% 
confidence.12 However, the analysis of the 450K arrays is compli-
cated by the inclusion of two different bead types associated to two 
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pipelines, which should mainly consist in eliminating or reduc-
ing the variability introduced during the experimental process, 
while maintaining the biological variation between conditions. 
Six different pipelines were considered (Fig. 1), each including a 
quality control step after which probes and samples were selected, 
followed by a normalization step (see Materials and Methods). 
The final process consisted in the identification of DM CpG sites.
A pipeline was positively scored whether (1) technical repli-
cates clustered together, (2) the correlation increased while (3) the 
average absolute difference between technical replicates decreased 
and (4) the bias between Infinium probe types decreased as well 
(for a detailed description see Materials and Methods section). 
Furthermore, we analyzed the number of DM sites that we were 
able to detect under different scenarios. In the sections below we 
will briefly describe the data sets, then the pipelines that we stud-
ied will be presented, evaluated and compared. Lastly, we will 
investigate the batch effect and its removal. Here, we define a 
batch as a subgroup of samples or experiments exhibiting a sys-
tematic non-biological difference that is not correlated with the 
biological variables under study.
Data sets. In order to analyze the pattern of technical vari-
ability reduction, we took advantage of data set A, which showed 
a large level of biological and technical replication and contrasted 
conditions with expected consistent differences in methylation. 
Specifically, we contrasted DNA methylation profiles obtained 
from monocytes (n = 43) or peripheral blood (PB, n = 53). 
Importantly, samples were randomly assigned to the slides and 
were processed together, to avoid additional bias in the vari-
ability. Clustering analysis showed that major differences exist 
between the two biological groups and that technical replicates 
cluster together even before any normalization, as evident from 
multidimensional and hierarchical clustering (Fig. S1A and B). 
The dispersion of the PB is higher as compared with that of 
monocytes, as expected, reflecting the heterogeneous vs. homo-
geneous composition of these sample types (Fig. S1A).
We studied the reduction of batch effect using data set B, 
which consisted of paired samples from healthy volunteers before 
and after supervised exercise training. Here major differences 
were manifest at the inter-individual level, as opposed to data set 
A, and minor differences between biological conditions (Fig. S1C 
and D). The definition of a batch was based on the qualitative 
assessment of differences between samples linked to processing 
day, slide or position, using a multidimensional scaling (MDS) 
plot. We noticed that major differences were related to the pro-
cessing day. Hereafter, we will refer to these groups of arrays with 
the same processing day simply as batches.
We performed biological and technical validations using two 
publicly available data sets. We replicated DM sites between 
monocytes and PB using data set C,20 while matched 450K and 
bisulfite pyrosequencing (BPS) data from data set D15 were used 
to check the performance of selected normalization methods for 
the estimation of the percentage methylation.
Testing different pipelines using dataset A. Patterns of vari-
ability reduction in absence of batch effect. We exploited data set 
A as a valuable resource for analyzing the technical variability 
reduction along the normalization steps. Actually, nine samples 
different chemical assays, Infinium I and Infinium II. Infinium I 
considers two bead types (methylated and unmethylated) for the 
same CpG locus, both sharing the same color channel, whereas 
Infinium II utilizes a single bead type and two color channels.12 
Dedeurwaerder et al.15 showed that Infinium II assays have larger 
variance and are less sensitive for the detection of extreme meth-
ylation values, which is probably associated to the dual-channel 
read-out, thus rendering the Infinium I assay a better estimator 
of the true methylation state. A “peak-based correction” method 
that rescales the Infinium II data on the basis of the Infinium 
I data was first developed, although a number of recent works 
highlighted potential problems with this method.15-17 Afterwards, 
SWAN (subset-quantile within array normalization) introduced 
sub-quantile normalization for the methylated and unmethylated 
channels separately, assuming that the distribution of the probes 
with similar number of CpGs should be similar, irrespective of 
probe type.16 A second sub-quantile normalization method (SQN) 
considered different probe categories to obtain quantiles and cor-
rect for the probe-type bias.17 Finally, a novel model-based normal-
ization algorithm (Beta Mixture Quantile dilation, BMIQ) was 
recently developed and compared favorably with other methods.18
A proper normalization is key in the analysis first to avoid 
any enrichment toward any probe type in the differential meth-
ylation analysis, and second because identifying contiguous dif-
ferentially methylated regions from single CpG sites requires the 
avoidance of technical variation especially for those sites posi-
tioned within the tested regions.19 There have been several efforts 
to develop new methodologies, and comparisons have been made 
using small data sets. To the best of our knowledge, there is yet 
no comprehensive comparison between methodologies in large 
number of samples that evaluates in detail the technical variabil-
ity over the pipeline and the effect in the identification of differ-
ential methylated probes.
To address the above-mentioned problems, we therefore com-
pared different analysis pipelines and performed a careful evalua-
tion of the variability along each step of the pipelines. Specifically, 
here we focused on the resolution of the variability into its techni-
cal and biological constituents, when methylation arrays are “con-
taminated” either with a bias between Infinium I and Infinium 
II probe design types or a batch effect. We used two independent 
data sets with extensive level of biological and technical replica-
tion and rigorous design, in order to assess (1) the reduction of 
the technical variability during normalization, (2) the removal of 
probe design type bias, (3) the effective reduction of batch effect 
and (4) the identification of differentially methylated (DM) sites. 
We identified the pipelines that were suitable to reduce the tech-
nical variability and highlighted that only those incorporating a 
probe-type correction step provided consistent measurements for 
DM analysis. In particular, BMIQ, a newly develop algorithm,18 
provided simultaneous correction for probe design and reduction 
of technical variability, in a consistent and reproducible way.
Results
In the current work, we focused on evaluating the changes in 
technical variability and the effect of different normalization 
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normalization, although the amplitude was small and the cor-
relation already high before normalization (Figs. 2A and 5). The 
M-values after normalization showed an effective reduction of 
the noise, evaluated by the absolute difference between technical 
replicates, although to a different extent for different ranges of 
M-value (Fig. 2B–D), with the best performance for low methyl-
ated positions. Looking at the density plots multiple peaks may be 
identified originating from the different density profiles of type I 
vs. type II Infinium probes (Fig. 3A and B). We employed here 
a color adjustment followed by a quantile normalization (QN) 
on the pooled signal intensities of methylated and unmethylated 
probes, before calculating methylation estimates (β or M values). 
QN is a common procedure in high throughput data analysis to 
reduce between-sample variation and it optimally centered the 
signal between arrays, correcting for influence of the position on 
the slide (Fig. S4). However, it did not reduce the probe-type 
bias, as expected (Fig. 3B). Therefore, we included a further step 
by performing BMIQ (beta mixture quantile dilation) on quan-
tile-normalized data. BMIQ is a recently developed model-based 
correction method, which has been proven to optimally elimi-
nate the bias between probe types.18 Indeed, we verified that the 
bias was effectively reduced (Figs. 3C and 6B), and the technical 
variability not amplified, since the deviation between technical 
replicates was not increased after BMIQ or in some cases was 
further reduced as compared with QN (Fig. 6A). Additionally, 
even when BMIQ alone was applied to raw data, we were able to 
detect a reduction of technical variability for six out of nine pairs 
(Fig. 6A) and a removal of probe type bias (Fig. 3D).
had at least one technical replicate and biological groups were 
represented to a satisfactory degree. Importantly, because (1) the 
assignment to arrays was randomized, (2) we did not observe any 
potential known confounder driving a clustering plot (i.e., slide 
or array) and (3) we used data from samples processed together 
in the same array facility, we assumed that negligible source of 
variation came from factors unrelated to the biological vari-
ables, or in other words that the variation between conditions 
was fairly larger than the variability introduced by any poten-
tial batch effect. Actually, principal component analysis (PCA) 
showed that the first two components, accounting for ~20% of 
the variability, were highly correlated with the contrasted groups 
(monocytes vs. PB), while the components associated with slide 
and array accounted for a smaller part (Fig. S3).
We first considered a lumi-based pipeline, as specifically 
explained in Methods section. After quality control, 473,097 
out of 485,577 probes were filtered in (97.4%) and 95 out of 
96 samples remained. One sample was excluded because of 
overall low intensity and abnormal methylation M profile (not 
shown). Filtered-out probes included 65 SNPs (from Illumina 
manifest), 11,648 probes on Chr X or Y and 767 probes with 
detection p value > 0.01 in > 5% of the samples. The probe 
intensities appeared to be properly normalized (Fig. S4), except 
for a small region of low intensity values for one subject, which 
however was consistent between technical replicates, hence puta-
tively originating from sample-specific characteristics. Next, we 
observed that the distance between technical replicates generally 
decreased and a global increase of correlation was observed after 
Figure 1. The workflow to compare pipelines. six pipelines were considered in this study, as explained in the main text. Using data set a, we run all the 
pipelines, selecting the one to be tested with data set B, which also allows the evaluation of the correction for batch effect.
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according to sample type. SWAN is a within-sample normaliza-
tion procedure, however it has been proposed for reduction of 
between-samples technical variability.16 We tested this hypothesis 
on our data set, showing that a very narrow decrease of the devia-
tion between technical replicates occurred after SWAN, indepen-
dently of M-value (Fig. 4B–D). At the same time, the correlation 
structure was maintained and we observed that on average the 
correlation increased within conditions but decreased between 
conditions (Fig. 4A; Fig. S6).
We also evaluated the pipeline described by Touleimat and 
Tost17 that we denoted here as SQN, referring to the subset quantile 
Afterward, we exploited a minfi-based pipeline on the same 
data set, to verify the effect of different preprocessing and nor-
malization processes. After quality, 473,115 out of 485,577 probes 
were filtered in (97.4%) and 95 samples remained. One sample 
was excluded because of overall bad control plots and anomalous 
methylation profile (not shown). Filtered-out probes included 65 
SNPs (from Illumina manifest), 11,289 probes on Chr X or Y 
and 1,108 probes with minfi detection p value > 0.01 in > 5% 
samples. After SWAN (subset within-array normalization), the 
bias between probe types was reduced, the M-value density got 
effectively normalized (Fig. 5) and the samples correctly clustered 
Figure 2. Evaluation of the lumi pipeline. (A) The difference in sample correlation (upper panel) or Euclidean distance (lower panel) between quantile 
normalization (QN) and raw data. For convenience, only samples represented by two or three technical replicates are shown. a gray bar indicates the 
samples from monocytes, whereas a black bar denotes the samples from peripheral blood (pB). Replicates belonging to the same pair are consecu-
tively located on each row or column. The color code indicates a decrease (blue) or an increase (yellow) in correlation or distance. (B) The absolute 
deviation between technical replicates in raw, color adjusted and QN data shows the consistent reduction of the technical variability after normaliza-
tion. (C and D) The logarithmic ratio between the variability after QN and the variability on raw data are shown for pB (C) and monocytes (D). For each 
probe, we calculated the average M-values and the corresponding mean absolute difference between technical replicates. The log2 ratio between QN 
and raw data was used to check the performance of the normalization in reducing the variability and the presence of possible bias for sites with low or 
high levels of methylation. The red line indicates the loess fitting.
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probes were filtered in (97%) and one sample was excluded. The 
distribution of the methylation estimates (β and M values) resulted 
normalized (Fig. S8A), whereas the bias between probe types was 
not eliminated (Fig. S8B). Moreover, the technical variability was 
not reduced, which we could evaluate by increased average absolute 
difference, decreased correlation and increased distance between 
technical replicates after normalization (Fig. S8C–F).
Comparative analysis between the different pipelines. In order to 
compare the performance of the pipelines, we considered three 
benchmarks: (1) the reduction of the bias between Infinium I 
and II, (2) the reduction of the variability between technical rep-
licates and (3) the ability of identifying DM probes.
Reduction of the probe bias in the 450K array. The capabil-
ity of reducing the probe type bias was evaluated through the 
analysis of the deviation between pairs of adjacent probes, one 
from each design and within 200 bp of each other. As shown in 
Figures 3B and 6B, between-sample normalization techniques, 
normalization performed within. After quality control, 473,864 
autosomal probes out of 485,577 probes were filtered in (97.6%) 
and one sample was excluded. The algorithm performed SQN on 
the methylation estimates (β values) using the “relation to CpG” 
to calculate the reference quantiles, i.e., probes were categorized 
according to their position with respect to CpG islands as pro-
vided by Illumina (CpG Island, S shore, S shelf, N shore, N shelf 
or outside).17 The distribution of the methylation estimates 
(β and M values) resulted overlapping for all samples (Fig. S7A). 
However, although the bias between probe types was actually 
reduced (Fig. 6B; Fig. S7B), the technical variability was abnor-
mally amplified, which we could evaluate by increased average 
absolute difference, decreased correlation and increased distance 
between technical replicates after normalization (Fig. S7C–F).
Finally, we evaluated the control normalization and back-
ground subtraction performed on GenomeStudio (Illumina) and 
denoted here as GS. 473,097 autosomal probes out of 485,577 
Figure 3. Lumi pipeline does not incorporate an adjustment for probe design type, which is obtained with BMIQ. The raw (A), QN normalized (B) and 
QN + BMIQ (C) densities of M-values are shown either for each sample, or as the average density for Infinium I or Infinium II probe design. (D) BMIQ 
alone is also suitable for eliminating the probe design type bias.
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assessed how close the technical replicates resulted after normal-
ization, by evaluating their average absolute difference, as pro-
posed for Illumina 27K arrays.21 Overall, we assessed that the 
best performance was obtained after performing lumi-based 
QN + BMIQ or BMIQ alone. Actually, the impact on the vari-
ability reduction was minor after SWAN and unfavorable after 
SQN or GS, when evaluating the discrepancy between technical 
replicate pairs (Figs. 2, 4 and 6; Figs. S7 and S8).
Differential methylation analysis. Initially, we compared the 
different pipelines for their ability of detecting DM between 
monocytes vs. PB. Thus, we obtained the difference in M val-
ues as effect size (ΔM), p values and FDR-corrected p values. 
We addressed the problem of identifying statistically significant 
like QN on signal intensity, cannot correct for this bias when 
reducing sample-to-sample dispersion. Nevertheless, the most 
effective correction was obtained with BMIQ alone or in com-
bination with QN, which were both effective in reducing the 
bias with a bigger extent as compared with the other methods 
considered here, in agreement to what was originally reported 
(Fig. 6B).18 The advantage was also shown by the comparison 
of the densities of M values, after stratification for probe type, 
which revealed no difference in the amplitudes after correction 
(Fig. 3C and D).
Reduction of the technical variability. We evaluated the reduc-
tion of the technical variability as one of the key goals to achieve, 
after the pre-processing and normalization steps. We carefully 
Figure 4. Evaluation of the minfi pipeline. (A) The difference in sample correlation (upper panel) or Euclidean distance (lower panel) between sWaN 
and raw data. For convenience, only samples represented by two or three technical replicates are shown. color codes and positions of the samples are 
the same as Figure 2. (B) The absolute deviation between technical replicates in raw and sWaN-normalized data shows the reduction of the technical 
variability after normalization. (C and D) The logarithmic ratio between the variability after sWaN and the variability on raw data are shown for pB (C) 
and monocytes (D). For each probe, we calculated the average M-values and the corresponding mean absolute difference between technical repli-
cates, as explained in Figure 2.
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DM sites, we fitted a latent class analysis as described in Methods 
section,22,23 to predict the class membership of each CpG site as 
being DM or not. We exploited the output of the six different 
pipelines to obtain six binary variables specifying if the site was 
DM of not-DM, using two simple thresholds: (1) FDR adjusted 
p < 0.05 or (2) FDR adjusted p < 0.05 and |ΔM| > 1. We selected 
the second threshold because we showed that the specificity 
reached the maximum at the expense of dropping the sensitivity 
is some cases, which however was still the highest using BMIQ 
alone or in combination with QN (Fig. S11).
In principle, a feature selection based on the dual threshold 
of adjusted p value < 0.05 and |ΔM| > 1 ensures a more real-
istic selection of probes, as it is currently done on gene expres-
sion analysis with microarrays. Table 1 and Figure 7C report 
the number of DM sites. Indeed, after correction for probe type 
with BMIQ, we obtained homogeneous fold changes, irrespec-
tive of probe design type, and more sites were reported as DM 
because of the improved estimation of the fold change for type 
II probes. This explained why we obtained more DM position 
after the application of the BMIQ algorithm. The threshold was 
not completely arbitrary, but chosen on the basis of previous 
observations, as described below (see Du et al.24). In contrast to 
change in methylation, in the presence of probe type bias. 
Therefore, we used volcano plots to compare p values and ΔM 
(Fig. 7A; Fig. S9). We observed that Type II probes have over-
all smaller amplitude in methylation change, the ΔM appeared 
more compressed without any probe design adjustment and 
two distinct populations appeared in a volcano plot. However, 
BMIQ, SWAN, SQN or GS corrected this bias although to a dif-
ferent extent (Fig. 7A; Fig. S9).
We initially compared the distribution of p values obtained 
with different approaches and looked at the correlation between 
them. Without a reference method to count true positives and 
true negatives on the basis of a threshold, we could initially 
verify that a strong correlation for the top-ranked items existed, 
which are more likely to be true positives. Hence, selecting top-
down the significant sites as explained in the method section, 
the Spearman correlation reached a maximum (ρ > 0.95), before 
starting to decrease when counting also non-significant sites, 
representing noise. However, SQN performed differently, and 
the maximum pairwise correlation with the other pipelines was 
always lower (Fig. 7B; Fig. S10). This behavior possibly suggests 
that the number of false positives was different after different 
pipelines. To test this hypothesis, without a known list of true 
Figure 5. Minfi pipeline incorporate an adjustment for probe design type, which is obtained with sWaN. The raw (A), and sWaN (B) densities of M-
values are shown either for each sample, or as the average density for Infinium I or Infinium II probe design.
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while intermediate-low methylated sites exclusively decreased 
their methylation in monocytes. Examples of specific meth-
ylation patterns of monocytes/lymphocytes associated genes are 
given in Figure S13. We then analyzed in detail the associated 
categories of each probe, using the provided Illumina Manifest 
File annotation and the DM sites (Fig. S14). Indeed, we observed 
a greater relative fraction of enhancer and DNase hypersensitivity 
sites (DHS) among DM sites, as compared with non-DM sites. 
Moreover, when comparing the link with annotated regulatory 
regions, we detected enrichment in groups classified as “cell type 
specific” but a deprivation of “promoter associated.” At the same 
time, the relative number of DM sites in CpG Islands (CGI) 
was also lower. As CGIs are enriched in promoters, it is possi-
ble that cell-specific CpG methylation is preferentially observed 
in enhancers, in agreement with the observation that enhanc-
ers show a better tissue specificity as compared with promot-
ers.26 This observation deserves further clarification. Moreover, 
while CGIs have been shown to co-localize with the promoters 
of all constitutively expressed genes and approximately 40% of 
those displaying a tissue restricted expression profile, non-CGI 
promoters are generally associated with restricted expression.27,28 
Indeed, when we selected only the DM probes in promoters 
(TSS200), a decreased fraction was located on CGI, as compared 
with non-DM, but an increased fraction was outside, including 
GCI shores, which have been described to have tissue-specific 
DNA methylation.29-31 This observation could explain why we 
are observing less DM sites in CGI when comparing monocytes 
vs. PB, i.e., a defined cell type vs. a heterogeneous cell population.
Validation of selected pipeline. Comparison with bisulfite pyro-
sequencing (BPS). We compared matched BPS-450K data from 
data set D,15 in order to check the agreement of the methylation 
M-values, β-values have non-constant variance, hence making 
difficult to choose a fixed threshold. However, Bibikova et al.12 
recommend a Δβ of 0.2 when analyzing Infinium450k arrays to 
detect DM sites with 99% confidence. The relationship between 
M and β values is not linear, therefore a Δβ = 0.2 cannot be 
directly translated in ΔM. However, for intermediate methylated 
sites (0.2 < M < 0.8), an approximated linear relationship exists24 
and Δβ = 0.2 roughly corresponds to ΔM = 1.33, which repre-
sents a threshold for maximum specificity. Hence, ΔM = 1 rep-
resented a compromise between increasing the true positive rate 
and not decreasing the detection rate. We provided replication of 
DM sites using data from an independent cohort (data set C)20 
and running the lumi:QN + BMIQ pipeline. We found that that 
88% of the DM CpGs in data set A were also DM in data set C 
(Figs. S12 and S13). Moreover, the use of the stringent threshold 
increased the percentage of replicated sites, thus confirming that 
it reduced the false positive rate.
We expected a considerable number of CpG sites to be specifi-
cally down-methylated in monocytes when compared with PB, 
because of the multiple blood cell types contained in this refer-
ence group. Actually, monocyte-specific CpG hypomethylation 
should be observed in promoters and likely on enhancers, as a 
prerequisite for lineage-specific gene expression.25 Therefore, in 
order to better visualize the pattern of variability in CpG sites, we 
performed PCA on M-values obtained after lumi:QN + BMIQ 
(Fig. 7D) observing that, without scaling the data, the first two 
components accounted for 98% of the variance and captured the 
average methylation level and the DM sites between monocytes 
and PB. Moreover, we gained a global vision of the relative DNA 
methylation of monocytes with respect to PB. Intermediate-high 
methylated sites increased or decreased their methylation levels, 
Figure 6. Elimination of probe design bias using BMIQ. (A) The absolute deviation between technical replicates after QN, QN + BMIQ or BMIQ show 
the consistent reduction of the technical variability after adjusting for probe design type. To calculate the difference, β-values were considered in this 
case. (B) The mean absolute difference between probe pairs (as defined in method section) shows that the reduction of the technical noise due to dif-
ferent design type, is optimally obtained using BMIQ, which is superior to sWaN, sQN or Gs.
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to subgroups of samples processed on the same day. More impor-
tantly, one biological factor was almost completely confounded 
with the batch, because one group was totally represented by 
male samples and the other has a majority of females. The first 
three principal components on raw data were highly associated 
with the processing group or the slide, together accounting for 
more than 40% of the variability (Fig. S3). On this data set we 
applied the lumi:QN + BMIQ pipeline, since this previously 
resulted in the best performance. We observed that technical rep-
licates on different batches did not cluster together, although the 
pairs of samples on the same batch (corresponding to the same 
subject before and after exercise training) were closely clustered 
together (Fig. S16). Clearly, a strong portion of the variability 
is dominated by non-biological source of variation, which how-
ever was reduced after batch adjustment. Indeed, we showed a 
reduction of the deviation from zero (Fig. 8A) and an increase in 
correlation between replicates (Fig. 8B) after correcting for the 
batch with the ComBat function. Moreover, a single group for 
values with an independent technique. Hence, we applied the 
lumi:QN + BMIQ pipeline on data set D and we calculated the 
bias from BPS values for 8 type II and 6 type I probes for which 
BPS data were reported and QC criteria were met. We verified 
that the deviation from BPS was reduced for type II probes after 
the selected pipeline (Fig. S15), confirming that the correction 
obtained with BMIQ for type II probes was actually advantageous.
Efficacy on removing strong batch effect. To this point we ana-
lyzed patterns of variability reduction in a data set that is not 
dominated by known strong batch effects. Because this kind 
of artifacts has been shown to have a substantial effect on high 
throughput experiments and in particular with Illumina meth-
ylation arrays,21 we asked whether we could highlight and reduce 
this additional layer of confounding variability, in particular 
when biological factors are admixed with non-random assign-
ment of samples to arrays or batches. To this end, we analyzed the 
variability on data set B, where two groups of samples processed 
on different days were present. The main effect was attributable 
Figure 7. The analysis of DM sites is influenced by the normalization process. (A) Volcano plots show the p value vs. the difference in methylation as 
calculated by limma. comparable amplitude in methylation difference is obtained only after adjusting with QN + BMIQ, BMIQ but not with QN only. 
(B) spearman correlation between p values obtained after different normalization options. The correlation was calculated progressively including 
probes from the ranked list of cpG sites, as described in Methods section. (C) Venn diagram showing the number of DM sites obtained after different 
pipelines. The threshold for claiming DM was FDR adjusted p < 0.05 aND absolute(ΔM) > 1. (D) pca of all probes denotes the pattern of variability. 
The color indicates the smoothed density (black = low, yellow = high). The first pc accounts for the average methylation level, while the second pc in-
dicates the direction of the methylation change in monocytes as compared with pB. DM sites are indicated as dots, with different colors for increased 
(green) or decreased (white) methylation. There is no sign of different behavior of type I or type II probes.
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safeguard to test for the ability of removal of unwanted variation. 
To our knowledge, data set A is actually unique for the num-
ber of technical replicates of clinical DNA samples profiled on 
Illumina 450K arrays. As already pointed out, all DNA samples 
were processed together, and the position on the arrays was com-
pletely randomized to account for slide and array position effect. 
Hence, given the substantial differences between the contrasted 
groups and the absence of any strong batch effect, we assumed 
that this scenario was optimal to compare pipelines and normal-
ization methods.
Importantly, here we performed QN on signal intensity and 
not on the methylation estimate. Although it has been noted that 
the assumptions of QN for methylation data might not hold,38 
given the potential global differences in the distribution of the 
methylation estimates of contrasted groups, lumi-based QN 
normalization is nevertheless performed on the signal intensity, 
rather than β or M values. Hence, when comparing similar tis-
sues and excluding sex chromosomes (as in our case), the fluo-
rescence intensity distribution appeared to be comparable and 
QN resulted a valid option as proposed for Illumina Human 
Methylation27 platform.21 Additionally, the artificial relation-
ship between the signal intensity and the position on the slide 
was properly eliminated after QN (Fig. S4), indicating that for 
this data set this normalization was beneficial. Careful examina-
tion of the signal and considerations on the study design should 
guide the application of this level of normalization, in order not 
to undermine the integrity of the biological signal.
The different performance of different probe designs in terms 
of methylation estimates was previously shown,12,15 and methods 
have been developed to deal with this bias.15-18 We focused on the 
parallel comparison of different approaches and pipelines, with 
the goal of providing an unbiased evaluation of the available 
tools. In our analysis the reduction of the technical variability 
was considered our main evaluation parameter. We considered 
the deviation between technical replicates and the bias between 
different probe types on the same sample as sources of unwanted 
variation and hence scored as positive any pipeline leading to a 
simultaneous reduction of both errors. On our data set, we vali-
dated BMIQ as the most proficient algorithm to reduce the probe 
design bias also in combination with QN. This result further 
validates the initial evaluation of BMIQ performance.18 In addi-
tion, we noticed that SQN reduced the probe type bias, but at the 
expense of an increased variability between technical replicates. 
This is most likely due to the effect of applying subset quantile 
normalization to the methylation estimates and not on signal 
intensities, and hence constraining the β values to have the same 
distribution. Indeed, this led to a reduction of the probe type bias 
as originally described,17 but without maintaining or decreasing 
the original distance between technical replicates.
all the replicates from the same subject was identified on a MDS 
plot (Fig. S16). Hence, we showed that it is possible to reduce 
the amount of variation due to non-biological factors, even in the 
presence of “contaminated” contrasts, where a sub-structure of 
the subjects could be potentially influential. However, whether 
the removal is complete or partial, it remained to be properly 
evaluated, because of the overlapping biological-technical factors.
Discussion
The principal conclusions may be summarized as follows. We 
observed that: (1) the effect of different normalization strategies 
is variable, the most effective being lumi:QN + BMIQ, (2) it is 
critical to correct for the probe design type, and BMIQ resulted 
the optimal method and (3) it is beneficial to correct for batch 
effects due to the intrinsic proprieties of highly parallel methyla-
tion profiling with Illumina arrays. In this section, first we will 
discuss the relevance of the data sets and the normalization meth-
ods used in this paper. Second, the correction for probe design 
type and batch effect will be examined and finally a few notes on 
differential methylation will be given.
The relevance of DNA methylation as a regulatory mecha-
nism is well established and its possible clinical application is an 
important research topic. A paramount example is represented 
by deregulation of DNA methylation in association with can-
cer, where methylation in gene body or Transcription Start Sites 
of tumor suppressor genes and de-regulation of DNA methyla-
tion machinery may occur.32-35 Eventually, DNA methylation has 
been also considered as a marker for solid cancer diagnostics.36,37 
Likewise, this epigenetic mark has been associated with other 
non-cancer diseases (reviewed in ref. 37), including autoimmune 
and neurological diseases. While the biological and clinical rel-
evance of DNA methylation is undoubtedly recognized, the 
technical platforms used for its assessment and the analysis pipe-
lines are rapidly evolving. In particular, Illumina Infinium 450K 
Human Methylation arrays, an extension of the previous 27K 
Human Methylation platform, are currently widely employed; 
although a consensus on analysis pipelines has not been reached, 
mainly because the introduction of two probe types on the same 
array has made the analysis process more complex. Therefore, in 
this work we described the comparison of analysis approaches 
for Illumina Infinium 450K arrays. The significance of this 
effort mainly relies on the data sets used, which we exploited 
as a resource to test the disentanglement of technical error, and 
on the detailed comparison of selected analysis methods. While 
the exact design, the biological conditions and the analysis of 
significance of the experimental data are beyond the scope of 
this publication and will be the topic of upcoming works, we 
took advantage of the level of technical replication as a reliable 
Table 1. Number of differentially methylated cpG sites resulting from the indicated pipelines (columns) and thresholds (rows)
Threshold lumi:QN lumi:QN + BMIQ lumi:BMIQ minfi:SWAN SQN GS
adjusted p < 0.05 215,822 203,159 157,646 162,113 219,288 171,898
adjusted p < 0.05
aND | ΔM | > 1
14,746 24,171 24,465 17,387 19,247 17,752
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arising from the presence of different white blood cells in the 
estimation of methylation profiles have been recently recognized 
and analyzed,20 pointing out the existence of reliable differences 
in the methylation levels for specific loci in different blood cells. 
We believed that the expected biological difference, the satisfac-
tory presence of both technical and biological replicates, and the 
randomized assignment represented ideal settings to verify the 
performance of different pipelines in identifying DM sites. The 
use of latent class analysis22,23 to predict the unknown true state 
of CpG sites led to the proposal of sensitivity and specificity 
for each pipeline, although some limitation should be consid-
ered. One main assumption of latent class models is conditional 
independency of the methods being tested, which in our case 
might be violated because correlation exists between the out-
puts of different pipelines. However, when we further tested a 
model that included correlations among pipelines by adding a 
random effect, with the stringent threshold we obtained maxi-
mum sensitivity and specificity by using lumi:QN + BMQ or 
lumi:BMIQ.
In conclusion, to our knowledge this work represented the 
first attempt to systematically compare bioinformatics pipelines 
for the analysis of Illumina 450K methylation data, considering 
sufficient amount of technical and biological replication to score 
the results with a data-driven approach. We carefully examined 
the reduction of technical variability, validating BMIQ as the 
optimal normalization methods, also in combination with QN 
if required. We suggested guidelines to the evaluation of current 
and upcoming new pipelines, providing also a valuable refer-
ence data set for performance testing.
Materials and Methods
Profiling of DNA methylation. The DNA methylation pro-
files used in this study were generated from the Infinium 
HumanMethylation450K BeadChip, an array-based detection of 
methylation status of 485,577 sites on bisulfite-treated DNA.12,14 
It should be pointed out that in this manuscript we mainly 
define a batch a subgroup of samples that were processed 
together, on the same day or in a very short time. However, this 
definition should not be taken as absolute, because a clear defini-
tion of a batch results from careful examination of the data set, 
in order to identify what is an appropriate batch variable other 
than the processing group, as the slide or the array (i.e., position 
on the slide). We did not evaluate other popular approaches that 
do not use information on the source of unwanted variation, the 
exemplar being surrogate variable analysis,39 or simpler methods 
as regressing with the principal components, as the main focus 
here was highlighting the requirement for batch effect correc-
tion, rather than evaluating methods. Specifically, one biologi-
cal factor in data set B (the gender) was confounded with the 
main batch variable, the processing subgroup, and the presence 
of technical replicates was helpful in elucidating the decrease 
in variation. Although we observed an improvement, we cannot 
completely exclude that part of the variability is still accounted 
for by batch effect. Hence, the finest safeguard against this source 
of unwanted variation is a careful study design, coupled with a 
random assignment of the samples to the arrays, the inclusion of 
a method to account for batch effect and the presence of techni-
cal replicates, one for each processing subgroup.
The ultimate goal of most experimental designs is to provide 
a list of DM sites, obtained after a proper normalization. Hence, 
we tested the performance in achieving a number of DM sites 
after the selected pipelines. It should be noted that a rigorous 
evaluation should include an assessment of the specificity and 
sensitivity. However, this situation requires the availability of a 
reference method or data sets, in order to count true and false 
positives, as well as true and false negatives. For Illumina meth-
ylation data, public data set often report the independent vali-
dation of few loci, which are insufficient for a proper assessment 
of the specificity and sensitivity. Here we contrasted different 
DNA sources from two different cell populations, potentially 
harboring consistent biological differences. The consequences 
Figure 8. The elimination of unwanted batch effect further reduces the technical variability. after correcting for batch effect, we observed an increase 
of correlation (A) and a decrease of the absolute deviation (B) between technical replicates. (C) The logarithmic ratio between the variability after QN 
+ BMIQ + comBat and the variability on raw data are shown, calculated as explained in Figure 2.
344 Epigenetics Volume 8 Issue 3
were considered, in order to validate the DM probes in an inde-
pendent cohort.
Data set D (validation data set). Data from Dedeurwaerder 
et al. (GEO accession GSE29290)15 were used to validate the 
methylation estimates with bisulfite pyrosequencing (BPS). Six 
samples were considered, including HCT116 wild-type (WT) 
and double-knockout (DKO) cell lines. Matched BPS data were 
available for 15 CpG sites.
Lumi-based pipeline. We used GenomeStudio (Illumina) to 
generate final reports containing signal intensities and detection 
p values, which then were used as input files for this pipeline. No 
background subtraction or control normalization was applied 
within GenomeStudio. Bioconductor “lumi” package24,40 was 
used for quality control and normalization. Within this pack-
age, methylation levels β and M are defined as follows:
(1) 
(2) 
where I
M
 and I
U
 represent the fluorescence intensity originat-
ing form methylated or unmethylated CpG locus, respectively, 
and α is a constant. Notably, for Infinium I design, I
M
 and I
U
 
are derived from two different bead type, while for Infinium II 
design I
M
 and I
U
 signals originate from the same bead type, but 
using different colors to discriminate methylated vs. unmethyl-
ated locus. M values were always considered, unless otherwise 
specified.
The assays measuring 65 SNPs (from Illumina manifest) 
were first removed, then sample outliers were removed by 
inspecting (1) the overall signal intensity, (2) the distribution 
of M-values, (3) the number of detected sites and (4) the rela-
tionship between sample after hierarchical clustering or mul-
tidimensional scaling. Probes on chromosomes X and Y were 
removed to eliminate potential artifacts originating from the 
presence of a different proportion of males and females. Probes 
with a detection p value > 0.01 exceeding 5% of the samples 
were also filtered out. Color-bias adjustment (Col.Adj) and 
quantile normalization (QN) were performed on signal inten-
sities as implemented in lumi. Briefly, the QN works on total 
signal intensity, assuming that the distributions of the pooled 
methylated and unmethylated probes are similar for different 
samples. We then performed probe type bias adjustment begin-
ning with QN or raw data and using beta-mixture quantile nor-
malization (BMIQ) on β-values.18
The minfi pipeline. We used raw *.idat files as a starting point 
for this pipeline, based on the Bioconductor library “minfi.”38 
Within this package, β and M values are defined as follows: 
(3) 
(4) 
The same laboratory processed all the samples (BEA core facility, 
Karolinska Institute).
M-values to evaluate methylation levels. Throughout this 
study, we mostly evaluated methylation levels with M-values 
rather than β-values. β-values are defined as the ratio of the 
methylated probe intensity and the total signal intensity. They 
range from 0 to 1 and have the clear advantage of representing 
the percentage methylation for each site, although their vari-
ance has been shown to be non-constant,24 a result that we also 
observed in our data set. M-values represent the log2 ratio of 
the intensities of methylated and unmethlylated probes. When 
M-values were calculated instead, an approximate homoscedas-
ticity was obtained (Fig. S2), providing an advantage for most 
commonly used analysis methods, which assume constant vari-
ance. Specifically, we considered that using M-value represented 
a better alternative to β-values for analyzing the reduction of 
the technical variability and the performance of the analysis 
pipelines. We noticed however that the variability was slightly 
influenced by the computation method of the M-value for each 
pipeline, as revealed by the modest increase in the variability in 
the low end of the scatter plot in one case (Fig. S2).
Metrics for evaluation of the performance of the bioin-
formatics pipelines. An assessment of the performance was 
obtained evaluating the patterns of technical variability reduc-
tion, using several metrics: (1) hierarchical clustering (HCL) 
with Euclidean distance and average linkage, (2) clustering 
using Multidimensional Scaling (MDS), (3) the Pearson cor-
relation, (4) the average absolute difference between techni-
cal replicates, (5) the density profile of M-values, specifically 
examining for differences between Infinium probe types, (6) 
Principal Component Analysis (PCA) and (7) the absolute dif-
ference between adjacent probe pairs, one from each design and 
within 200 bp of each other (within probe clusters as described 
in Teschendorff et al.).18
Data set A (technical replicates data set). This data set con-
sisted of 85 samples. DNA from two cohorts was isolated either 
from Peripheral Blood (PB) or from CD14+ monocytes sorted 
from PB. Specifically, 50 samples from PB and 36 samples from 
monocytes were randomly assigned to 8 BeadChips with techni-
cal replicates and processed in one run (a total of 96 DNA sam-
ples). Eight samples were technically replicated in pairs, while 
one sample was represented in a trio of replicates (GEO accession 
GSE43976).
Data set B (paired sample/batch effect data set). This data 
set consisted of paired samples from 17 healthy volunteers par-
ticipating in the EpiTrain study. DNA was extracted from mus-
cle biopsies from vastus lateralis before and after a 3 mo period 
of supervised exercise training. Two batches were present: one 
BeadChip was processed in one day, while two BeadChips were 
processed together in a separate day. One subject had one techni-
cal replicate pair per condition, with one of the two members of 
the pair for each batch. DNA samples from the same subject were 
hybridized on the same BeadChip.
Data set C (validation data set). This is a subset of the data 
set studied by Reinius et al. (GEO accession GSE35069).20 Only 
samples from whole blood (n = 6) or CD14+ monocytes (n = 6) 
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p values and FDR corrected p values for the contrast of inter-
est. Here we compared monocytes vs. PB using autosomal data. 
CpG sites were selected as DM if adjusted p value < 0.05 and 
|ΔM| > 1. To compare the distribution of p values obtained 
after different normalizations, we partitioned the lists in blocks 
of 250 probes and calculated the Spearman correlation progres-
sively including them from the top to the bottom of the list. 
This procedure was repeated for each pipeline taking that pipe-
line as a reference (n), then ordering the probes in ascending 
order according to the corresponding p value and finally calcu-
lating the Spearman correlation with the p values obtained with 
another pipeline (k).
In order to compare DM sites obtained using pipelines, we 
exploited a latent class analysis approach, using the R library 
randomLCA.41 Two threshold were selected: (1) FDR adjusted 
p < 0.05 or (2) FDR adjusted p < 0.05 and |ΔM| > 1. Using the 
above thresholds, we created manifest binary variables indicat-
ing if a site was considered DM (1) or not-DM (0), then we 
counted the frequencies of the observed patterns comparing 
pipelines and then we fitted first a two latent class model (2LC) 
and then a two latent class model with random effect (2LCR) 
which includes correlation among pipelines.22,23 We finally esti-
mated the sensitivity and specificity values for each pipeline 
using the conditional outcome probabilities for the positive and 
negative classes.
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where I
M
 and I
U
 represent the fluorescence intensity originat-
ing form methylated or unmethylated CpG locus, respectively, 
and γ is a constant. Hence, the following relationship holds:
(5) 
We would like to remark that it is slightly different to the 
M-value defined in the lumi pipeline, where the constant is 
added to both numerator and denominator. Here the outliers 
were removed by inspecting the overall signal intensity, the dis-
tribution of M-values and the control probe profile. Probes with 
a minfi detection p value > 0.01 exceeding 5% of the samples 
were removed, as well as those on chromosomes X and Y and 
the assays measuring 65 SNPs (from Illumina manifest). Next, 
subset-quantile within array normalization (SWAN) was per-
formed.16 The assumption is that the distribution of intensities of 
probes with the same number of CpGs in the probe body should 
be similar regardless of design type.
The subset quantile normalization (SQN) pipeline. The 
pipeline described by Touleimat and Tost17 was applied here on 
GenomeStudio (Illumina) final reports containing signal intensi-
ties and detection p values. The algorithm performed (1) probe 
quality filtering based on detection p value, (2) removal of probes 
on sex chromosomes, (3) color bias adjustment and (4) SQN on 
the methylation estimates (β values) using the “relation to CpG” 
to calculate the reference quantiles.
Correction of the batch effect. We used either MDS or PCA 
to detect patterns of variability originating from a subset of sam-
ples. Next, we evaluated the association of the first five principal 
components with batch effect (processing day, slide or array), 
using a Wilcoxon or Kruskal-Wallis test. Finally, we applied the 
ComBat function in the R library sva,39 to account for and to 
eliminate biases in the M-values. The ComBat function performs 
an empirical Bayes adjustment to reduce batch effect. Batch effect 
correction was only applied to data set B.
Determination of differentially methylated (DM) sites. 
DM sites were defined using limma package on M values.40 
β values were transformed to M values using Eq. 4, when 
required. To account for the high correlation between techni-
cal replicates, we estimated the average correlation using linear 
mixed models for each gene and accounted for this prior weight 
in the linear model when for testing DM. Using limma, we 
could estimate the effect size (difference in M-values or ΔM), 
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